ophthalmology brenda and dry eye disease ARTIFICIAL TEARS – MOISTURIZING RELIEF.  Allergan is the clear artificial tears market leader. It is estimated that over 60 million people globally use artificial lubricating tears. We are proud to offer our leading brand of artificial tears, REFRESH, and a broad range of other tears products such as LIQUIFILM, CELLUVISC, CELLUFRESH and LACRI-LUBE around the world. REFRESH ENDURA is a breakthrough emulsion formulation that acts on all three tear layers (lipid layer, aqueous  layer and mucin layer) to provide relief of dry eye symptoms. As an emulsion drop, REFRESH ENDURA is used in clinical practice as part of the treatment strategy for managing dry eye. In addition, the extensive REFRESH product line includes REFRESH PLUS, the leading unit dose tear; REFRESH TEARS, the number one multi-dose product; REFRESH PM for overnight relief of dry eye; and REFRESH LIQUIGEL, which combines the strength of a gel with the convenience of a liquid eye drop. Additionally, Allergan markets CELLUVISC, the product most often recommended for severe dry eye; RELIEF, for fast relief of redness plus dry eye protection; and other tear products.  OCULAR INFECTION, INFLAMMATION AND ALLERGY – BRIDGING THE GAP. Allergan continues its efforts to be innovative in the eye care market and strives to offer a full range of products for ocular health. A clear leader among ophthalmologists with the fluoroquinolone OCUFLOX (ofloxacin ophthalmic solution 0.3%), Allergan also provides physicians with ZYMAR, a powerful new product to treat ocular infection due to susceptible bacteria. Approved by the FDA in 2003, ZYMAR is a fourth-generation fluoroquinolone with complete solubility, good tissue penetration and efficacy at low doses against a broad spectrum of organisms. The mechanism of action for ZYMAR also has been shown to slow the development of bacterial resistance.  Brenda, a 59-year-old real estate agent in Virginia, knows about the pain and frustration of dry eye disease. “My eyes were extremely red,” she says, “and I could not stand to be in the wind. Even being under a ceiling fan or in my car with the air conditioner running was impossible.” She is not alone. An estimated 1 million people in the United States suffer from moderate to severe dry eye disease. The incidence is expected to grow as the population ages. Brenda called to thank her doctor’s sales representative after one month on RESTASIS (cyclosporine ophthalmic emulsion 0.05%), the only therapeutic option available for people with chronic dry eye disease. “The difference is amazing,” she said. She can see and feel the improvements, and she’s using significantly less artificial tear product. Allergan is proud to be the pioneer in the dry eye market with RESTASIS, the first and only product proven to help restore the body’s ability to produce natural tears. Approved by the FDA in late 2002, the product will be the subject of a new direct-to-consumer advertising campaign in 2004.